Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CTH | P32929 | 1/20 | 0.38 |
| ▸ | CBS | P35520 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18205459 | 0.77 | — | — | |
| SCHEMBL23241590 | 0.72 | SLC22A6 (0.38) | SLC22A6TSHRCTHCBSTHPO | |
| SCHEMBL38290 | 0.72 | TDP1 (0.42) | SLC22A6TSHRCTHCBSTHPO | |
| SCHEMBL21858258 | 0.70 | — | — | |
| Ammonia Solution, Strong SCHEMBL11291766 | 0.70 | TDP1 (0.46) | SLC22A6TSHRCTHCBSTHPO | |
| SCHEMBL11150705 | 0.70 | TDP1 (0.40) | SLC22A6TSHRCTHCBSTHPO | |
| SCHEMBL11687090 | 0.70 | TDP1 (0.40) | SLC22A6TSHRCTHCBSTHPO | |
| SCHEMBL5681308 | 0.70 | TDP1 (0.40) | SLC22A6TSHRCTHCBSTHPO | |
| Ammonia Solution, Strong SCHEMBL11291772 | 0.70 | TDP1 (0.46) | SLC22A6TSHRCTHCBSTHPO | |
| SCHEMBL11388252 | 0.70 | TDP1 (0.40) | SLC22A6TSHRCTHCBSTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | SLC22A6 2166/4885TSHR 902/4885CTH 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.